Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

计划入组 900 人 · 首次发布于 2021 年 3 月 15 日

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

计划入组 478 人 · 首次发布于 2021 年 3 月 15 日

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

计划入组 22 人 · 首次发布于 2022 年 2 月 10 日

LIGA-20

HST-101

sIgA immunotherapy (Secretory IgA)

LISA GRIFFIN

United States

SIGA Technologies

India

LOPES & LIMA LTDA

Brazil

FDA Approves Lerodalcibep-liga (LEROCHOL) as Third-Generation PCSK9 Inhibitor for Cholesterol Management

FDA Approves Plozasiran for Familial Chylomicronemia Syndrome, Marking Breakthrough in Rare Lipid Disorder Treatment

FDA Accepts Review of Lerodalcibep for LDL Cholesterol Reduction